Akebia Therapeutics (AKBA) Other Non-Current Liabilities (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Other Non-Current Liabilities data on file, last reported at $2.5 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $2.5 million, down 50.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 million (down 50.65% YoY), and the FY2025 annual result was $3.0 million, down 42.69% from the prior year.
• Other Non-Current Liabilities eased to $2.5 million in Q1 2026 per AKBA's latest filing, from $3.0 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $83.1 million in Q1 2022 and troughed at $760000.0 in Q4 2022.
• A 5-year average of $19.8 million and a median of $5.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 4205.7% in 2022 and fell as far as 99.1% in 2022.
• A 5-year view of Other Non-Current Liabilities shows it stood at $760000.0 in 2022, then soared by 1138.82% to $9.4 million in 2023, then slumped by 44.77% to $5.2 million in 2024, then slumped by 42.69% to $3.0 million in 2025, then declined by 15.3% to $2.5 million in 2026.
• Business Quant data shows AKBA's Other Non-Current Liabilities at $2.5 million in Q1 2026, $3.0 million in Q4 2025, and $5.2 million in Q3 2025.